U.S. markets open in 42 minutes

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
50.56+1.56 (+3.18%)
Al cierre: 04:00PM EDT
51.11 +0.55 (+1.09%)
Antes de la apertura del mercado: 08:11AM EDT

Twist Bioscience Corporation

681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671
https://www.twistbioscience.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo919

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Emily Marine Leproust Ph.D.Co-Founder, Chairman & CEO1.37M153.71k1973
Dr. Patrick John Finn Ph.D.President & COO943.94kN/D1972
Ms. Paula GreenSenior Vice President of Human Resources618.48kN/D1968
Dr. William Charles Banyai Ph.D.Senior VP of Advanced Development, GM of Data Storage & Director711.34kN/D1955
Mr. Adam LaponisChief Financial OfficerN/DN/D1977
Mr. Robert F. WernerVP & Chief Accounting OfficerN/DN/D1973
Mr. Siyuan ChenChief Technology OfficerN/DN/DN/D
Dr. Aaron K. Sato Ph.D.Chief Scientific OfficerN/DN/DN/D
Mr. Chet GandhiChief Information OfficerN/DN/DN/D
Mr. Dennis ChoSenior VP, Chief Legal Officer & Corporate Secretary537.93kN/D1971
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Twist Bioscience Corporation a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 7; Compensación: 5.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.